Following this program, participants should be able to:

Improving Quality of Care for Lesbian, Gay, Bisexual, and Transgender (LGBT) Patients
•    Describe how rates of cancer screening uptake, incidence, and treatment outcomes in the LGBT populations compare to the general population and what may account for differences between these groups.
•    Discuss common disparities LGBT individuals experience during their cancer care.
•    Identify strategies to improve the quality of cancer care provided to LGBT patients and to provide welcoming and inclusive practice environments.

Substance Use in Patients with Cancer
•    Understand risk factors for substance use in patients with cancer.
•    Discuss the potential implications of substance use among patients with cancer.
•    Identify tools that can be used to screen for or monitor substance misuse/abuse.

Optimizing Oral Therapy in Kidney Cancer
•    Compare the current understanding on the benefits of targeted therapies in the treatment of first line, second line, and subsequent lines of therapy renal cell carcinoma.
•    Learn the adverse events associated with the oral therapies available for advanced RCC and strategies to manage them.
•    Provide education to patients on safe and effective administration of oral therapy emphasizing the importance of adherence to therapy.

Management of Cardiovascular Toxicities Associated with TKI Therapy
•    Describe the different types of cardiovascular toxicities associated with TKI therapy.
•    Discuss the current strategies for monitoring cardiac function and management of cardiovascular toxicities of TKI therapy.
•    Develop an individualized treatment plan based on the toxicity profile of TKI therapy, cardiovascular risk assessment and early identification of signs and symptoms.

Management of Hypersensitivity Reactions to Systemic Therapy
•    Discuss the pathophysiology of the different types of infusion-related HSR to chemotherapeutic agents and MABs.
•    Review the strategies used for the prevention and treatment of infusion-related HSR to systemic therapy.
•    Develop an evidence-based treatment plan for the management of infusion-related HSR in patients receiving systemic therapy.  

Safe Handling of Hazardous Drugs
•    Explain the health risks associated with occupational exposure to hazardous drugs or drug waste.
•    Understand standards for safe handling of hazardous drugs by oncology nurses, as specified in USP <800>.
•    Identify barriers to compliance with recommendations for safe handling of hazardous drugs in the oncology setting.

Implementing a CAR T-Cell Therapy Program
•    Summarize key symptoms associated with CAR T-cell therapy.
•    Outline current therapeutic strategies used as supportive care measures for adverse events stemming from CAR T-cell therapy.
•    Identify mechanisms that can be utilized to implement a CAR T-cell therapy program.